Table 1.
Baseline clinical and demographic patient characteristics
| Variable | N | No bounce (N = 3073) | Bounce (N = 1404) | p-Value |
|---|---|---|---|---|
| Biochemical failure | 339 | 245 (7.8%) | 94 (6.4%) | 0.0741 |
| Bounce | 1404 | 0 (0.0%) | 1404 (100.0%) | <0.001 |
| Race | <0.001 | |||
| African American | 904 | 522 (17.0%) | 382 (27.2%) | |
| Caucasian | 3573 | 2551 (83.0%) | 1022 (72.8%) | |
| Treatment | 0.0379 | |||
| Brachytherapy | 4004 | 2731 (88.9%) | 1273 (90.7%) | |
| EBRT + brachytherapy | 473 | 342 (11.1%) | 131 (9.3%) | |
| T-stage | 0.1178 | |||
| T2a or lower | 4117 | 2815 (91.6%) | 1302 (92.7%) | |
| T2b-T2c | 342 | 242 (7.9%) | 100 (7.1%) | |
| Unknown | 18 | 16 (0.5%) | 2 (0.1%) | |
| N-stage | 0.1352 | |||
| N0 | 4342 | 2974 (96.8%) | 1368 (97.4%) | |
| N unknown | 135 | 99 (3.3%) | 36 (2.6%) | |
| Baseline PSA | 0.0299 | |||
| <10 | 3882 | 2643 (86.0%) | 1239 (88.3%) | |
| 10–20 | 583 | 424 (13.8%) | 159 (11.3%) | |
| Unknown | 12 | 6 (0.2%) | 6 (0.4%) | |
| Gleason’s score | 0.001 | |||
| <7 | 3024 | 2022 (65.8%) | 1002 (71.4%) | |
| 7 | 1355 | 979 (31.2%) | 376 (26.8%) | |
| Unknown | 98 | 72 (2.3%) | 26 (1.9%) | |
| Marital status | 0.1279 | |||
| Married | 2296 | 1607 (52.3%) | 689 (49.1%) | |
| Not married | 2177 | 1463 (47.6%) | 714 (50.9%) | |
| Unknown | 4 | 3 (0.1%) | 1 (0.1%) | |
| Risk group | <0.001 | |||
| Low | 2552 | 1688 (54.9%) | 865 (61.6%) | |
| Intermediate | 1924 | 1385 (45.1%) | 539 (38.4%) | |
| Age at diagnosis | 64.4 (6.6) | 65.3 (6.7) | 62.4 (6.3) | <0.001 |
EBRT = external beam radiation therapy.
The sample includes patients who received brachytherapy either alone or in combination for low- or intermediate-risk prostate cancer within the Department of Veterans Affairs.